- Home
- BWAY vs GOSS Comparison
BWAY vs GOSS Comparison
Compare BWAY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- GOSS
- Stock Information
- Founded
- BWAY 2003
- GOSS 2015
- Country
- BWAY Israel
- GOSS United States
- Employees
- BWAY N/A
- GOSS N/A
- Industry
- BWAY Medical/Dental Instruments
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- BWAY Health Care
- GOSS Health Care
- Exchange
- BWAY Nasdaq
- GOSS Nasdaq
- Market Cap
- BWAY 201.1M
- GOSS 203.3M
- IPO Year
- BWAY 2019
- GOSS 2019
- Fundamental
- Price
- BWAY $10.22
- GOSS $1.16
- Analyst Decision
- BWAY Strong Buy
- GOSS Strong Buy
- Analyst Count
- BWAY 2
- GOSS 4
- Target Price
- BWAY $14.25
- GOSS $7.75
- AVG Volume (30 Days)
- BWAY 34.0K
- GOSS 1.5M
- Earning Date
- BWAY 05-13-2025
- GOSS 05-15-2025
- Dividend Yield
- BWAY N/A
- GOSS N/A
- EPS Growth
- BWAY N/A
- GOSS N/A
- EPS
- BWAY 0.08
- GOSS N/A
- Revenue
- BWAY $43,457,000.00
- GOSS $124,590,000.00
- Revenue This Year
- BWAY $351.53
- GOSS N/A
- Revenue Next Year
- BWAY $21.84
- GOSS $190.37
- P/E Ratio
- BWAY $51.42
- GOSS N/A
- Revenue Growth
- BWAY 26.86
- GOSS N/A
- 52 Week Low
- BWAY $5.67
- GOSS $0.50
- 52 Week High
- BWAY $11.79
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- BWAY 56.53
- GOSS 55.35
- Support Level
- BWAY $10.15
- GOSS $1.09
- Resistance Level
- BWAY $11.06
- GOSS $1.20
- Average True Range (ATR)
- BWAY 0.51
- GOSS 0.09
- MACD
- BWAY 0.00
- GOSS 0.00
- Stochastic Oscillator
- BWAY 54.72
- GOSS 69.01
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.